Neela Manish Bhatia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Neela Manish Bhatia has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Vinayak S. Marulkar
Department of Pharmaceutical Quality Assurance, Bharati Vidyapeeth College of Pharmacy, Kolhapur, India
3 shared publications - Anagha Ajagekar
Department of Pharmaceutical Quality Assurance, Bharati Vidyapeeth College of Pharmacy, Kolhapur, Shivaji University, Kolhapur, Maharashtra, India
1 shared publication Anagha Bhutnar
1 shared publicationAsma A. Mokashi
Department of Quality Assurance, Bharati Vidyapeeth College of Pharmacy, Kolhapur, India
1 shared publication- Asma A. Mokashi
Suryadatta Education Foundation's Suryadatta College of Pharmacy, HealthCare & Research (SCPHR), Survey No. 342, Bavdhan, Pune 411021, Maharashtra, India
1 shared publication Asma Mokashi
Department of Quality Assurance Bharati Vidyapeeth College of Pharmacy Kolhapur Maharashtra India
1 shared publication
Latest Publications
- 1 May 2026
- Published by Bentham Science Publishers Ltd. in Mini-Reviews in Medicinal Chemistry
- Vol. 26 (8) , 545-563
Breast Cancer: Challenges in the Treatment and Prodrug Strategies
Breast cancer (BC) remains a leading cause of mortality worldwide, with treatment complicated by tumor heterogeneity, drug resistance, and therapy-related toxicities. Despite advances in chemotherapy, immunotherapy, and surgery, these challenges continue to limit therapeutic outcomes. Among emerging strategies, prodrugs have shown promise. These pharmacologically inactive compounds are designed to undergo enzymatic or chemical conversion in the body, releasing the active drug selectively in target tissues, thereby improving drug delivery, enhancing efficacy, and reducing systemic toxicity. Prodrug strategies targeting specific molecular features of tumors, such as the tumor microenvironment (TME), offer potential solutions to issues like poor drug solubility and bioavailability. Combining prodrugs with other therapeutic modalities, including immunotherapy and precision medicine, is actively being investigated to overcome drug resistance and enhance treatment response. Nevertheless, challenges remain, including the complexity of designing prodrugs that can be efficiently activated within the TME, as well as scalability and manufacturing costs. Future research leveraging nanotechnology, personalized medicine, and artificial intelligencedriven drug discovery is expected to drive innovations in prodrug-based therapies. Integrating these approaches may enable more effective and individualized treatments for BC, particularly in cases refractory to conventional therapies. This review highlights the current status, challenges, and future directions of prodrug development in breast cancer therapy, underscoring their potential to transform the treatment landscape.
- 1 May 2026
- Published by Bentham Science Publishers Ltd. in Mini-Reviews in Medicinal Chemistry
- Vol. 26 (8) , 545-563
Breast Cancer: Challenges in the Treatment and Prodrug Strategies
Breast cancer (BC) remains a leading cause of mortality worldwide, with treatment complicated by tumor heterogeneity, drug resistance, and therapy-related toxicities. Despite advances in chemotherapy, immunotherapy, and surgery, these challenges continue to limit therapeutic outcomes. Among emerging strategies, prodrugs have shown promise. These pharmacologically inactive compounds are designed to undergo enzymatic or chemical conversion in the body, releasing the active drug selectively in target tissues, thereby improving drug delivery, enhancing efficacy, and reducing systemic toxicity. Prodrug strategies targeting specific molecular features of tumors, such as the tumor microenvironment (TME), offer potential solutions to issues like poor drug solubility and bioavailability. Combining prodrugs with other therapeutic modalities, including immunotherapy and precision medicine, is actively being investigated to overcome drug resistance and enhance treatment response. Nevertheless, challenges remain, including the complexity of designing prodrugs that can be efficiently activated within the TME, as well as scalability and manufacturing costs. Future research leveraging nanotechnology, personalized medicine, and artificial intelligencedriven drug discovery is expected to drive innovations in prodrug-based therapies. Integrating these approaches may enable more effective and individualized treatments for BC, particularly in cases refractory to conventional therapies. This review highlights the current status, challenges, and future directions of prodrug development in breast cancer therapy, underscoring their potential to transform the treatment landscape.
- Open Access
- 25 October 2024
- Published by Marmara University in Journal of Research in Pharmacy
- Vol. 29 (5) , 1792-1801
Development and validation of a UV-Spectrophotometric method using methanol for the simultaneous estimation of doxycycline and voriconazole in pharmaceutical formulations
The development and validation of a UV-spectrophotometric method for the simultaneous estimation of doxycycline and voriconazole in pharmaceutical formulations are presented in this study. This method was designed to address the limitations of existing analytical techniques by providing a simple, accurate, and efficient approach suitable for routine quality control and therapeutic monitoring. Methanol was selected as the solvent, and estimation was done using the multiwavelength method of analysis. Estimation of doxycycline was done by recording a difference of absorbance at 358 and 402 nm while the estimation of voriconazole was done by recording absorbance difference at 428 and 463 nm. The difference of absorbance for estimation of two drugs is recorded for elimination of interference of the other drug. The method demonstrated excellent linearity, with calibration curves showing strong correlation coefficients. Accuracy was confirmed through satisfactory recovery rates, and precision was validated with %RSD values below 2% for both intraday and inter-day measurements. The method exhibited robustness and ruggedness, maintaining consistent performance under varying experimental conditions and across different analysts. Low limits of detection and quantification underscored the method's sensitivity. This UV-spectrophotometric method offers significant practical advantages, including reduced analysis time and cost-effectiveness, making it highly suitable for adoption in pharmaceutical laboratories. The study concludes that this method is a valuable tool for improving drug quality and safety, contributing to advancements in pharmaceutical sciences and supporting enhanced productivity in drug analysis.
- 25 October 2024
- Published by Marmara University in Journal of Research in Pharmacy
- Vol. 29 (5) , 1792-1801
Open AccessDevelopment and validation of a UV-Spectrophotometric method using methanol for the simultaneous estimation of doxycycline and voriconazole in pharmaceutical formulations
The development and validation of a UV-spectrophotometric method for the simultaneous estimation of doxycycline and voriconazole in pharmaceutical formulations are presented in this study. This method was designed to address the limitations of existing analytical techniques by providing a simple, accurate, and efficient approach suitable for routine quality control and therapeutic monitoring. Methanol was selected as the solvent, and estimation was done using the multiwavelength method of analysis. Estimation of doxycycline was done by recording a difference of absorbance at 358 and 402 nm while the estimation of voriconazole was done by recording absorbance difference at 428 and 463 nm. The difference of absorbance for estimation of two drugs is recorded for elimination of interference of the other drug. The method demonstrated excellent linearity, with calibration curves showing strong correlation coefficients. Accuracy was confirmed through satisfactory recovery rates, and precision was validated with %RSD values below 2% for both intraday and inter-day measurements. The method exhibited robustness and ruggedness, maintaining consistent performance under varying experimental conditions and across different analysts. Low limits of detection and quantification underscored the method's sensitivity. This UV-spectrophotometric method offers significant practical advantages, including reduced analysis time and cost-effectiveness, making it highly suitable for adoption in pharmaceutical laboratories. The study concludes that this method is a valuable tool for improving drug quality and safety, contributing to advancements in pharmaceutical sciences and supporting enhanced productivity in drug analysis.
- 2 September 2024
- Published by Springer Nature in Phytochemistry Reviews
- Vol. 24 (4) , 2869-2906
Chalcone and derived natural products: versatile scaffolds for multiple targets in treatment of Type 2 diabetes
- 2 September 2024
- Published by Springer Nature in Phytochemistry Reviews
- Vol. 24 (4) , 2869-2906
Chalcone and derived natural products: versatile scaffolds for multiple targets in treatment of Type 2 diabetes
- Open Access
- 30 August 2024
- Published by Asian Publication Corporation in Asian Journal of Chemistry
- Vol. 36 (9) , 2115-211
Dual Tumor Targeting Ability of Fatty Acyl (Amide) Amino Acid Alkyl Ester Conjugates : In vitro Cytotoxicity and DNA Cleavage based Bioactivity
In this work, the bioactivity of fatty acyl (amide) amino acid alkyl esters through cytotoxicity and DNA cleavage properties were assessed. The synthetic method utilized HBTU-catalyzed amide formation between the carboxyl group of stearic acid and linoleic acid and the amine group in L-glutamic acid dimethyl ester and L-methionine methyl ester. The conjugates were elucidated using FTIR, NMR and mass and evaluated for cytotoxicity (COLO-205, A549 cell lines). Conjugates 10a-c exhibited selective growth inhibitory effects on cancer cell lines, while no impact was detected on normal cells. Overall, there was a significant reduction in the proliferation of human colorectal (COLO-205) and lung cancer (A549) cancer cells. Conjugates 10a-c also exhibited favourable cytocompatibility on normal murine fibroblast (L929) cells. Conjugate 10c showed promiscuous in vitro cytotoxicity against colorectal (COLO-205) and lung (A549) cancer cells compared to conjugates 10a and 10b.
- 30 August 2024
- Published by Asian Publication Corporation in Asian Journal of Chemistry
- Vol. 36 (9) , 2115-211
Open AccessDual Tumor Targeting Ability of Fatty Acyl (Amide) Amino Acid Alkyl Ester Conjugates : In vitro Cytotoxicity and DNA Cleavage based Bioactivity
In this work, the bioactivity of fatty acyl (amide) amino acid alkyl esters through cytotoxicity and DNA cleavage properties were assessed. The synthetic method utilized HBTU-catalyzed amide formation between the carboxyl group of stearic acid and linoleic acid and the amine group in L-glutamic acid dimethyl ester and L-methionine methyl ester. The conjugates were elucidated using FTIR, NMR and mass and evaluated for cytotoxicity (COLO-205, A549 cell lines). Conjugates 10a-c exhibited selective growth inhibitory effects on cancer cell lines, while no impact was detected on normal cells. Overall, there was a significant reduction in the proliferation of human colorectal (COLO-205) and lung cancer (A549) cancer cells. Conjugates 10a-c also exhibited favourable cytocompatibility on normal murine fibroblast (L929) cells. Conjugate 10c showed promiscuous in vitro cytotoxicity against colorectal (COLO-205) and lung (A549) cancer cells compared to conjugates 10a and 10b.
- Open Access
- 29 February 2024
- Published by Medic Scientific in Journal of Medical pharmaceutical and allied sciences
- Vol. 13 (1) , 6326-6336
Network ethnopharmacological and molecular docking based evaluation of the anti-breast cancer activity for ayurvedic botanicals acting on hypoxia-inducible factor-1
The recognized root causes of breast cancer aggressiveness, resistance to therapy, and poor prognosis encompass hypoxia-inducible factors (HIFs), the HIF-dependent cancer hallmarks angiogenesis and metabolic reconfiguration.There is enough evidence to suggest that HIF is involved in the progression of breast cancer.Information for the network was gathered from the following databases: Dr. Duke's, IMPPAT, PubChem, Binding DB, UniProt, and DisGeNET. The network was created using the Cytoscapeprogramme. Screened bioactives having similarity index more than 0.6 from polypharmacology approach were subjected to docking studies with HIF-1 (PDB ID: 1H2K) with PyRx software and the ligands with good docking score was further explored for molecular docking interaction analysis. The number of bioactives having interaction with HIF-1, equal to or greater than 0.6 from Ashwagandh, Shatavari, Neem, Alsi seeds, Methi, Haldi, Ghritkumari, Yashtimadhu, and KadiPatta was 12, 9, 2, 6, 12, 11, 5, 10, and 3, respectively. On performing the docking against the target…
- 29 February 2024
- Published by Medic Scientific in Journal of Medical pharmaceutical and allied sciences
- Vol. 13 (1) , 6326-6336
Open AccessNetwork ethnopharmacological and molecular docking based evaluation of the anti-breast cancer activity for ayurvedic botanicals acting on hypoxia-inducible factor-1
The recognized root causes of breast cancer aggressiveness, resistance to therapy, and poor prognosis encompass hypoxia-inducible factors (HIFs), the HIF-dependent cancer hallmarks angiogenesis and metabolic reconfiguration.There is enough evidence to suggest that HIF is involved in the progression of breast cancer.Information for the network was gathered from the following databases: Dr. Duke's, IMPPAT, PubChem, Binding DB, UniProt, and DisGeNET. The network was created using the Cytoscapeprogramme. Screened bioactives having similarity index more than 0.6 from polypharmacology approach were subjected to docking studies with HIF-1 (PDB ID: 1H2K) with PyRx software and the ligands with good docking score was further explored for molecular docking interaction analysis. The number of bioactives having interaction with HIF-1, equal to or greater than 0.6 from Ashwagandh, Shatavari, Neem, Alsi seeds, Methi, Haldi, Ghritkumari, Yashtimadhu, and KadiPatta was 12, 9, 2, 6, 12, 11, 5, 10, and 3, respectively. On performing the docking against the target…
- Open Access
- 1 January 2024
- Published by Compuscript, Ltd. in BIO Integration
- Vol. 5 (1) , 970
Integrated Network Ethnopharmacology, Molecular Docking, and ADMET Analysis Strategy for Exploring the Anti-Breast Cancer Activity of Ayurvedic Botanicals Targeting the Progesterone Receptor
Background: In women, breast cancer is currently among the most common cancers and the second major cause of cancer-related mortality. One therapeutic target for breast cancer is the progesterone receptor (PR), which can be inhibited by specific PR modulators. Methods: Current anti-cancer medications have notorious adverse effects. Consequently, an urgent need exists to identify less hazardous, more effective medicines with few to no adverse effects. One strategy uses ancient herbal remedies to create medications derived from nature. Herein, we used data from the Dr. Duke, IMPPAT, PubChem, Binding DB, UniProt, and DisGeNET databases to construct a network in Cytoscape 3.10.0. Through a polypharmacology approach, bioactives with similarity indices greater than 0.6 were screened and docked with the PR. The top ten ligands with good docking scores were further subjected to interaction analysis in AutoDock v.4.2 software. We additionally analyzed the ADMET properties of the phytochemicals. Results: Procurcumenol and alpha-turmerone exhibited superior interactions with PR, with binding affinities of −7.85 kcal/mol. All compounds met Lipinski’s rule of five and were effective ligands for the PR according to ADMET data analysis. Our findings suggest that procurcumenol and alpha-turmerone may serve as potential anti-breast cancer agents; specifically targeting the PR in breast cancer cells. Conclusion: Understanding of anti-breast cancer activity can be facilitated through experimental validation of network analysis and molecular docking findings.
- 1 January 2024
- Published by Compuscript, Ltd. in BIO Integration
- Vol. 5 (1) , 970
Open AccessIntegrated Network Ethnopharmacology, Molecular Docking, and ADMET Analysis Strategy for Exploring the Anti-Breast Cancer Activity of Ayurvedic Botanicals Targeting the Progesterone Receptor
Background: In women, breast cancer is currently among the most common cancers and the second major cause of cancer-related mortality. One therapeutic target for breast cancer is the progesterone receptor (PR), which can be inhibited by specific PR modulators. Methods: Current anti-cancer medications have notorious adverse effects. Consequently, an urgent need exists to identify less hazardous, more effective medicines with few to no adverse effects. One strategy uses ancient herbal remedies to create medications derived from nature. Herein, we used data from the Dr. Duke, IMPPAT, PubChem, Binding DB, UniProt, and DisGeNET databases to construct a network in Cytoscape 3.10.0. Through a polypharmacology approach, bioactives with similarity indices greater than 0.6 were screened and docked with the PR. The top ten ligands with good docking scores were further subjected to interaction analysis in AutoDock v.4.2 software. We additionally analyzed the ADMET properties of the phytochemicals. Results: Procurcumenol and alpha-turmerone exhibited superior interactions with PR, with binding affinities of −7.85 kcal/mol. All compounds met Lipinski’s rule of five and were effective ligands for the PR according to ADMET data analysis. Our findings suggest that procurcumenol and alpha-turmerone may serve as potential anti-breast cancer agents; specifically targeting the PR in breast cancer cells. Conclusion: Understanding of anti-breast cancer activity can be facilitated through experimental validation of network analysis and molecular docking findings.
- 1 December 2023
- Published by Bentham Science Publishers Ltd. in Current Bioactive Compounds
- Vol. 19 (10) , 1
Bioactive Natural Products for Breast Cancer Chemoprevention and Treatment
Background: In addition to being one of the deadliest tumors, breast cancer is also one of the most difficult to cure. Due to the serious side effects of current breast cancer treatments and the rise in drug resistance, current drugs are losing their effectiveness. Potential Natural Bioactives: Bioactive natural compounds target various pathophysiological pathways involved in the development and progression of cancer and hence have the ability to prevent both the growth of breast cancer and the advancement of metastatic disease concurrently. : Natural anticancer compounds have been shown to be effective, complementary treatment may be of great assistance in this case. Clinical Outcomes: Nutraceuticals and popular folk remedies may provide benefits over manufactured pharmaceuticals since they have fewer side effects and less toxicity in both in vitro and in vivo studies. A variety of natural compounds have been shown to reduce the aggressiveness of breast cancer, inhibit the growth of malignant cells, and alter the pathways involved in cancer development and progression. Either by directly affecting certain biological targets, such genes, or by indirectly stabilising conjugates that have an impact on metabolic processes, natural compounds called phytochemicals can enhance human health. Mechanistic Pathways: There are many promising bioactive natural products that can be used to treat breast cancer, including those that inhibit aromatase activity, target HIF-1 signaling, inhibit cytoplasmic signaling, modulate epigenetic regulation, modulate estrogen signaling pathways, or work in chemosensitivity/adjuvant therapy (such as resveratrol, epigallocatechin-3-gallate, and eugenol).
- 1 December 2023
- Published by Bentham Science Publishers Ltd. in Current Bioactive Compounds
- Vol. 19 (10) , 1
Bioactive Natural Products for Breast Cancer Chemoprevention and Treatment
Background: In addition to being one of the deadliest tumors, breast cancer is also one of the most difficult to cure. Due to the serious side effects of current breast cancer treatments and the rise in drug resistance, current drugs are losing their effectiveness. Potential Natural Bioactives: Bioactive natural compounds target various pathophysiological pathways involved in the development and progression of cancer and hence have the ability to prevent both the growth of breast cancer and the advancement of metastatic disease concurrently. : Natural anticancer compounds have been shown to be effective, complementary treatment may be of great assistance in this case. Clinical Outcomes: Nutraceuticals and popular folk remedies may provide benefits over manufactured pharmaceuticals since they have fewer side effects and less toxicity in both in vitro and in vivo studies. A variety of natural compounds have been shown to reduce the aggressiveness of breast cancer, inhibit the growth of malignant cells, and alter the pathways involved in cancer development and progression. Either by directly affecting certain biological targets, such genes, or by indirectly stabilising conjugates that have an impact on metabolic processes, natural compounds called phytochemicals can enhance human health. Mechanistic Pathways: There are many promising bioactive natural products that can be used to treat breast cancer, including those that inhibit aromatase activity, target HIF-1 signaling, inhibit cytoplasmic signaling, modulate epigenetic regulation, modulate estrogen signaling pathways, or work in chemosensitivity/adjuvant therapy (such as resveratrol, epigallocatechin-3-gallate, and eugenol).